Why the Advanced Radioisotope
Manufacturing Facility Matters
The infrastructure, investment and specialist expertise behind entX's ambition to advance Australia's medical isotope manufacturing capability.

Establishing a commercial medical isotope manufacturing facility requires far more than laboratory space. It demands specialised infrastructure, significant capital investment, complex regulatory approvals and a highly skilled workforce.
Through its Advanced Radioisotope Manufacturing Facility (ARMF), entX is bringing these critical capabilities together to support the future production of medical isotopes in Australia.
Significant Barriers to Entry
Operating a facility of this nature requires purpose-built hot cells and shielded enclosures, advanced radiation safety systems, specialised engineering and strict regulatory compliance.
These requirements represent a substantial investment of both time and capital. Hot cells alone can cost millions of dollars, while obtaining regulatory approvals and developing the specialist workforce needed for safe, compliant operations can take years.
As a result, the combination of infrastructure, regulatory expertise and operational capability required to establish an advanced radioisotope manufacturing facility creates significant barriers to entry, particularly in Australia.
Building Australia's Medical Isotope Capability
Through the ARMF, entX has brought these essential components together, establishing the infrastructure and expertise needed to support commercial medical isotope production.
This capability represents an important foundation for IsoMedica and entX's broader ambitions in the growing radiopharmaceutical and targeted alpha therapy markets.
By combining specialised infrastructure, regulatory capability and an experienced team, entX is working to establish a differentiated position in Australia's medical isotope manufacturing sector.
OTher Projects
